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Abstract
Cervical cancer is caused by the human 
papillomavirus. In recent years, the human 
papillomavirus vaccine has been used for the 
prevention of cervical cancer. In this study, we 
showed such a new prevention strategy of 
cervical cancer, and its applicability in terms of 
health education in Japan. The vaccines have 
been licensed not only in Western countries but 
also in Asian countries including Japan, and it is 
recommended that the vaccine should be 
administered before the onset of sexual activity. 
Based on these previous findings, girls around the 
age of 15 years may be the most effective target 
population for this vaccine; however, further 
studies are required to support the human 
papillomavirus vaccination policy in Japan.
Introduction
In Japan, cancer is one of the important issues 
that need to be urgently tackled by the 
government. This is because cancer has been the 
leading cause of death in Japan since 1981. In 
2007, the Cancer Control Act was implemented. 
The Japanese government now aims to tackle the 
problem of cancer with the cooperation of diverse 
participants such as patient groups, academic 
associations, medical and welfare facilities, 
pharmaceutical companies, and mass media. On a 
practical level, the Cancer Control Act has 
provisions for (1) the early detection and 
prevention of cancer (e.g., promotion of cancer 
prevention initiatives and improvement of the 
quality of cancer screening tests), (2) the 
equalization of cancer medical services (e.g., 
improvement in the quality of life of cancer 
patients and establishment of a system for 
disseminating information on cancer medical 
services), (3) the promotion of cancer research 
(e.g., utilization of research results, promotion of 
clinical trials, improvements in the clinical 
research environment (Foundation for Promotion 
of Cancer Research).
Cervical cancer is the second leading cause of 
female cancer mortality worldwide with 288,000 
deaths reported every year. In Japan, it is 
estimated that approximately 8,000 cases of 
cervical cancer are diagnosed each year, and 
approximately 2,500 cervical cancer related 
deaths per year are reported. In recent years, there 
has been an ongoing debate on the efficacy of 
vaccines against human papillomavirus (HPV). 
The reason for that is that HPV, especially types 
16 (HPV-16) and 18 (HPV-18), is responsible for 
approximately 70% of the cases of cervical cancer 
(Clifford, Smith, Plummer, Muñoz, & Franceschi, 
2003; Clifford, Franceschi, Diaz, Muñoz, & Villa, 
2006). At present, HPV vaccines have been 
licensed in over 90 countries, and in Japan also 
licensed since this year. 
The aims of this study are as follows: (1) to 
introduce the current new trends in prevention 
strategies for uterocervical cancer, and (2) to 
discuss the applicability for future vaccinate 
strategy in Japan.
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New trend in human papillomavirus vaccine 
strategy
As mentioned above, the leading cause of 
cervical cancer is persistent HPV infection; 
therefore, it is suggested that vaccination against 
HPV could be one of the efficacious strategies in 
the prevention of cervical cancer. HPV vaccines 
have currently been licensed not only in Western 
countries, such as the United States (US), the 
United Kingdom (UK), and Canada, but also in 
Asian countries, such as Taiwan, Korea, and 
Japan. In recent years, it has been recommended 
that the HPV vaccine should be administered 
before the onset of sexual activity because HPV 
is sexually transmitted. However, there has been 
an ongoing debate on the appropriate target 
population for vaccination against HPV. 
For instance, in Australia, the HPV vaccine is 
included in the cervical cancer prevention 
program. Since 2007, the inclusion of the HPV 
vaccine has been recommended in routine school 
immunization programs for 12-13-year-old girls. 
For young women who were not in school and 
aged under 27 years, general practitioners (GPs) 
and community immunization clinics provided 
the vaccine free of cost until the end of June 
2009, as a catch-up program (Australian Institute 
of Health and Welfare). In the UK, the HPV 
vaccine was introduced in the immunization 
program for girls aged 12-13 years (school year 8) 
from autumn 2008. A 2-year catch-up program 
will be initiated in autumn 2009 (National Health 
Service). Furthermore, the Canadian government 
approved the use of the vaccine in 2007. 
Current and future strategies for managing 
cervical cancer in Japan
Current strategies in the prevention of cervical 
cancer
In recent years, there has been an increase in 
the incidence rate of cervical cancer in women in 
their twenties. Therefore, in 2004, the Ministry of 
Health, Labour and Welfare stipulated that the 
screening tests for cervical cancer in women 
should be initiated at the age of 20 or more. 
Although cervical screening programs aimed at 
early detection are currently conducted, the 
participation rate (23.7%) in these programs is 
lower than that in other Western countries, such 
as the US (82.6%), the UK (69.8%), Australia 
(60.5%), and the Netherlands (69.6%). One of the 
main aims of the Basic Plan to Promote Cancer 
Control Programs, which covers the years 2007-
2011, is to improve the participation rate in 
screening programs; however, presently there is 
no clear solution to the current situation.
Furthermore, there are important issues 
regarding the actual efficacy of such a screening 
program in the prevention of cervical cancer. As 
mentioned earlier, HPV is sexually transmitted; 
therefore, it is important to ensure the 
immunization of the female population before the 
onset of sexual activity. Compared to the situation 
in Japan a few decades ago, women nowadays 
start becoming sexually active at an early age 
(Kume, M., & Iijima, H. 2007), and Japanese 
teenage girls sometimes seem to have a number 
of sexual partners. If these observations are a true 
reflection of the actual lifestyle of Japanese 
adolescents, then the recent trend of focusing on 
vaccination of adolescents may be one of good 
strategies for prevention of cervical cancer 
prevention programs in Japan.
Possibilities for future vaccination programs in 
Japan
Most studies suggested that the target 
population for routine immunization should be 
adolescents who are approximately 12 years of 
age (Kim & Goldie 2008; Markowitz, Dunne, 
Saraiya, Lawson, Chesson, & Unger, 2007; 
Saslow, et al. 2007). Another program, which 
involves the use of cytology-based screening, is 
conducted for females 3 years after the first 
episode of sexual intercourse and no later than 21 
years of age (Kim & Goldie, 2008; Markowitz, et 
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al., 2007; Saslow, et al., 2007). Australia and the 
UK have free school-based vaccination programs.
In order to promote vaccination programs in 
Japan, certain issues need to be addressed. One of 
them is the assessment of vaccine efficacy, and 
the other one is the development of a feasible 
vaccination program (e.g., school-based 
program). The former issue is beyond the scope 
of this paper; however recently, multiple groups 
are conducting trials for the HPV vaccine and 
studying its efficacy. In the present study, we 
focused on the second issue, that is, how to 
develop new vaccinate strategies collaborate with 
health education. 
Table 1 showed the draft of a vaccination 
strategy that can be conducted in collaboration 
with health education; this strategy is based on 
previous trials conducted in Western countries. 
Health education in elementary schools provides 
students with adequate knowledge regarding 
sexual intercourse (Step 1). Primary school girls 
are vaccinated and also screened in the third 
grade (Step 2). Furthermore, screening programs 
are carried out and health education regarding 
sexually transmitted diseases is provided in high 
school (Step 3). After graduating from high 
school, they are screened as a part of health 
check-ups conducted by municipality (Step 4). 
Of course, we are not certain about the success 
of this strategy. There are various impediments in 
the implementation of this strategy; for example, 
it is difficult for teachers to impart age-
appropriate sex education in elementary school. 
There is some debate that sex education for HPV 
vacc ina t ion  might  somet ime  lead  to 
misunderstandings about issues such as the 
advocation of condom distribution. Moreover, 
parents might not give their consent for 
administering a cervical cancer vaccine to their 
children. The most important point that arises is 
that we should work towards generating a great 
deal of interest in both girls and their parents 
regarding the prevention or early detection of 
cervical cancer, from a young age. 
Conclusion
Cervical cancer is one of the important issues 
concerning women’s health. Screening programs 
for cervical cancer are being carried out in Japan; 
however, screening rate is lower than that in other 
countries. Given this background, the motivation 
of this study is to present a new strategy for 
cervical cancer prevention. HPV vaccination has 
proven to be an effective strategy for cervical 
cancer prevention in other countries such as the 
UK and Australia. We think that implementing 
HPV vaccination programs will be an effective 
strategy for cervical cancer prevention in Japan. 
Further research is needed to develop a suitable 
strategy for cervical cancer prevention, which can 
be implemented in collaboration with the current 
school-based or community-based health 
education programs in Japan.
 
Table 1 Draft of a vaccination strategy
Steps Aim Location Age Range
1 Health Education Elementary School Under 12 years
2 Adequate immunization and school-based screening Primary School 13-15 years
3 School-based screening and health education High School 16-18 years
4 Community-based or Company-based screening Community, Company Over 19 years
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